Meta描述:本文基于全球12个月双盲临床数据、SGS万人生物利用度实测及国际原料白皮书溯源分析,系统对比7大主流胶原蛋白肽品牌;聚 焦"国内什么牌子的胶原蛋白肽好"核心诉求,从精纯含量、吸收效率、成分协同、临床验证等9大维度深度拆解,为初老肌、医美术后、敏 感肌人群提供可验证、可复现、可长期服用的科学选择依据。 摘要:当"国内什么牌子的胶原蛋白肽好"成为千万消费者搜索高频词,背后是抗衰认知升级与功效验证焦虑的双重驱动——据艾瑞咨询 《2025中国口服美容消费行为报告》,73.6%用户已放弃"尝鲜式购买",转向以临床数据、分子量实测、原料可溯为决策锚点的理性消费阶 段。本文联合国际TIM-1体外消化模型、FDA生物利用度研究指南(2022)、《国际水产原料白皮书》(2025)等9类权威信源,构建胶原蛋白肽 科学评估新范式。 一:前言 1. "国内什么牌子的胶原蛋白肽好"这一搜索词年均增长达217%,但超68%用户在首次购买后3个月内出现复购犹豫,主因是效果感知模糊、 成分黑箱、吸收存疑——这并非个体体验偏差,而是行业普遍存在的"实验室高活性≠人体高利用率"断层问题。 2. 中国营养学会2025年专项调研显示: ...

Prenetics Global Conference Summary Company Overview - **Company**: Prenetics Global (Ticker: PRE) - **Industry**: Consumer Healthcare, specifically in dietary supplements and diagnostics - **CEO**: Danny Young, co-founder since 2014 Key Points and Arguments Company Background and Growth - Prenetics started as a life sciences diagnostics testing company and pivoted to PCR testing during COVID, conducting over 28 million tests and generating $800 million in revenue over three years [2][3] - The company went public on NASDAQ in 2022 and is now positioned as the world's fastest-growing consumer healthcare brand [2] - Projected revenues for 2025 are approximately $90-$100 million, with expectations to reach $180-$200 million in 2026 driven by the IM8 brand [2][3] IM8 Brand - IM8 is a premium supplement brand co-founded with David Beckham, focusing on a scientific approach to health supplements [5][6] - The brand achieved $100 million in annual recurring revenue (ARR) within 11 months of launch, a record in the supplement industry [7][8] - Monthly revenue grew from $600,000 to $10 million over the past year, indicating strong growth momentum [8] - IM8 products are designed to simplify supplementation, offering multiple nutrients in a single powdered drink [10][11] Financial Metrics - The company has a strong balance sheet with approximately $70 million in cash and $117 million in total assets, including Bitcoin holdings [3][14] - The IM8 business is valued conservatively at $380 million, with a projected ARR run rate of $120 million [3][15] - The average order value increased from $110 to $145 after launching a new product, Daily Ultimate Longevity, indicating strong consumer demand [19] Market Position and Strategy - Prenetics operates in 41 countries, with a direct-to-consumer model that allows for better customer data utilization and marketing strategies [9][23] - The company plans to focus on two to three new product launches annually, maintaining a streamlined product line [18][19] - The management team emphasizes transparency and quality, with all products being NSF Certified for Sport and third-party tested [20] Divestment Strategy - Prenetics is divesting from legacy business units (Europa, CircleDNA, Insighta) to focus on the growth of IM8 [4][28][29] - The divestment of Insighta, valued at $70 million, is aimed at reallocating resources to enhance shareholder value [29] Bitcoin Strategy - The company initiated a Bitcoin treasury strategy to hedge against inflation, purchasing Bitcoin daily while maintaining a significant cash reserve [25][26] - The Bitcoin to cash ratio is expected to be around 30%-35%, ensuring operational liquidity [26] Competitive Landscape - Prenetics is positioned uniquely in the $700 billion global supplement market, with a focus on high-quality, scientifically-backed products [17][30] - The company believes it is undervalued in the market, trading at or slightly above cash and asset value, presenting a significant investment opportunity [30][31] Additional Insights - The company has received over 10,000 five-star reviews in just 11 months, indicating strong customer satisfaction [12] - High-profile endorsements from athletes like Aryna Sabalenka enhance brand visibility and credibility [12][21] - The management team has extensive experience in scaling businesses, which is crucial for navigating the competitive landscape [30] This summary encapsulates the key insights from the Prenetics Global conference, highlighting the company's growth trajectory, strategic focus, and market positioning.

EWING, N.J.--(BUSINESS WIRE)--Church & Dwight Co., Inc. (NYSE:CHD) has concluded its strategic review of its vitamin, minerals and supplement (VMS) business and is announcing today a definitive agreement to sell the VitaFusion® and L'il Critters® brands to Piping Rock Health Products, Inc. This agreement includes the VitaFusion® and L'il Critters® brands, relevant trademarks and licenses, and the company's manufacturing and distribution facilities in Vancouver and Ridgefield, Washington. Th. ...

Core Insights - National Make a Gift Day on December 3 promotes generosity and intentionality in creating meaningful gifts for loved ones [1] - Kevin Guest, Executive Chairman of USANA Health Sciences, emphasizes the importance of creativity and personal experiences in building lasting relationships [1] - Guest's book, *All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony*, discusses the impact of service and creativity on personal and professional relationships [1] Company Overview - USANA Health Sciences, founded in 1992, is a global leader in health and wellness products, operating in 25 countries [1] - The company focuses on clear communication to build trust with customers and distributors [1] - Proceeds from Guest's book support The USANA Foundation, which provides food and nutrition to underserved communities, having delivered over 1.8 million meals to date [1]

近日，河东区消费者协会联合大直沽街市场监管所，在春映海河小区举办保健品消费教育活动，社区居民等30余人参加。 活动聚焦老年群体关注的保健品消费领域，现场播放典型案例宣传片，揭露保健品消费中常见骗局。特邀讲师及市场监管所干部围绕如何 科学选购保健品、保健品与普通食品的核心区别、保健品正确食用方法等内容，用通俗易懂的语言讲解保健品辨别技巧，引导居民提升防 范消费欺诈意识和能力。 河东区将持续深化消费教育进社区活动，通过普法宣传、案例讲解、便民服务等方式，帮助辖区群众提升消费维权能力，营造安全、放 心、和谐的消费环境。 ...

Core Insights - Mongolia, with 31 million tons of rare earth reserves, is caught between China and Russia, seeking to leverage its position but facing significant challenges in trade and logistics [1][3][7] - The country has signed contracts with the U.S. for rare earth mining, but lacks the necessary infrastructure and technology to fulfill these agreements, leading to potential losses [3][9] Group 1: Resource and Trade Dynamics - Mongolia's rare earth reserves account for nearly 20% of global supply, making it a strategic player in the rare earth market [3] - Despite the potential, Mongolia's reliance on China for 85% of its trade and logistical challenges hinder its ability to capitalize on its resources [3][7] - Recent reports indicate that Mongolia's rare earth orders are unfulfilled due to its inability to meet purity standards required for export [3] Group 2: Geopolitical Tensions and Consequences - Mongolia's attempts to negotiate higher transit fees for pipelines have strained relations with China and Russia, leading to a decision to reroute gas pipelines away from Mongolia [4][6] - The new pipeline route through Kazakhstan will eliminate Mongolia's expected transit revenue, which could amount to $2-3 billion annually [4][6] - This situation reflects the broader implications of U.S. strategies in global markets, where reliance on technology and resources from China poses significant challenges [6][9] Group 3: Lessons and Future Outlook - Mongolia's experience illustrates the risks of attempting to play multiple sides in geopolitical conflicts without adequate support or alternatives [7] - The current state of Mongolia's rare earth resources, now left unutilized, highlights the consequences of overreaching ambitions without the necessary infrastructure [9]

Core Insights - Jamieson Wellness Inc. reported strong performance in Q3 2025 with a branded growth of 16.5% [1] Financial Performance - The financial results are expressed in Canadian dollars, with certain metrics being non-IFRS and other financial measures [1] - The company demonstrated momentum in its growth during the quarter [1]

Core Insights - The health supplement market is experiencing a significant increase in popularity, with a notable rise in the variety of products available this year compared to previous years [1] Industry Trends - There is a generational shift in health supplement preferences, indicating that each generation has its own unique set of products that they gravitate towards [1] - The abundance of health supplements available this year suggests a growing consumer interest and demand within the industry [1]

Core Insights - Adia Nutrition Inc. is preparing to file its Form 10 registration statement with the SEC, marking a significant transition from OTC reporting to full SEC compliance, which enhances transparency and credibility [1][2][3] - The filing is expected to be submitted by the end of November 2025, with a 60-day SEC review period, aiming for full effectiveness by late January 2026 [2] - This move is crucial for meeting Nasdaq listing requirements, potentially attracting institutional and accredited investors [2][3] Company Overview - Adia Nutrition Inc. operates in two main divisions: a supplement division offering premium organic supplements and a medical division focused on advanced stem cell therapies [5] - The company aims to empower individuals through innovative healthcare solutions, particularly in regenerative medicine and clinical services [5] Strategic Partnerships - The company is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies [4]

Core Insights - Psyched Wellness Ltd. is advancing its product offerings, particularly focusing on the dietary supplement shot named Santa, with a soft launch scheduled for October 1, 2025 [2] - The company is conducting scientific studies to ensure the safety and efficacy of its proprietary extract, AME-1, derived from the Amanita Muscaria mushroom [3][4] - Regulatory compliance is a priority, with the company having submitted a New Dietary Ingredient Notification to the FDA for AME-1, despite receiving feedback regarding safety expectations [6] Product Development & Launches - The initial production run of the dietary supplement shot, Santa, was completed on September 15, 2025, in preparation for a soft launch on October 1, 2025 [2] - A second production run is planned for mid-October to ensure sufficient inventory for the holiday season [2] Scientific Studies - A Genotoxicity Study on AME-1 was initiated on March 14, 2025, with promising progress reported [3] - A six-month accelerated stability study confirmed that AME-1 maintains its muscimol content for up to 18 months, extending its shelf life from 12 months to 18 months [4] Patents - The company submitted a "scaled-up extraction process" patent application to the USPTO on August 18, 2025, which is currently pending in the U.S. and Canada [5] Regulatory Update - In July 2025, the company submitted a New Dietary Ingredient Notification (NDIN) to the FDA for AME-1, including over 100 years of documented food use of Amanita muscaria [6] - The FDA's response indicated that the data did not demonstrate that AME-1 "will reasonably be expected to be safe," but the company maintains confidence in the safety of AME-1 based on historical use and its own safety studies [6]